Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
59 hedge funds and large institutions have $31.6M invested in Kezar Life Sciences in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 26 closing their positions.
34% more capital invested
Capital invested by funds: $23.6M → $31.6M (+$8.02M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.05% less ownership
Funds ownership: 5.41% → 5.36% (-0.05%)
27% less funds holding
Funds holding: 81 → 59 (-22)
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
85% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.2M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$452K |
| 3 |
Renaissance Technologies
New York
|
+$313K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$266K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.11M |
| 2 |
Goldman Sachs
New York
|
-$435K |
| 3 |
Jane Street
New York
|
-$295K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$266K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$217K |
KZR Hedge Fund Activity: Q3 2024 in Review
59 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2024, worth a combined $31.6M — up 34% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KZR and 4 opened new positions — a net loss of 22 holders — while 22 trimmed existing stakes and 14 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $2.2M. The largest seller was Sphera Funds Management, cutting an estimated $1.11M.
- 59 institutional investors held Kezar Life Sciences (KZR) as of Q3 2024, down from 81 in Q2 2024.
- Funds reported $31.6M of Kezar Life Sciences stock for Q3 2024, up 34% quarter-over-quarter.
- 4 funds opened new Kezar Life Sciences positions in Q3 2024 and 26 closed out, a net change of -22 holders.
- The largest Kezar Life Sciences buyer in Q3 2024 was Tang Capital Management, an estimated $2.2M added.
- The largest Kezar Life Sciences seller in Q3 2024 was Sphera Funds Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2024.